TY - JOUR
T1 - Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult
T2 - An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group
AU - the Transatlantic Australasian Retroperitoneal Sarcoma Working Group
AU - Tseng, William W.
AU - Swallow, Carol J.
AU - Strauss, Dirk C.
AU - Bonvalot, Sylvie
AU - Rutkowski, Piotr
AU - Ford, Samuel J.
AU - Gonzalez, Ricardo J.
AU - Gladdy, Rebecca A.
AU - Gyorki, David E.
AU - Fairweather, Mark
AU - Lee, Kyo Won
AU - Albertsmeier, Markus
AU - van Houdt, Winan J.
AU - Fau, Magalie
AU - Nessim, Carolyn
AU - Grignani, Giovanni
AU - Cardona, Kenneth
AU - Quagliuolo, Vittorio
AU - Grignol, Valerie
AU - Farma, Jeffrey M.
AU - Pennacchioli, Elisabetta
AU - Fiore, Marco
AU - Hayes, Andrew
AU - Tzanis, Dimitri
AU - Skoczylas, Jacek
AU - Almond, Max L.
AU - Mullinax, John E.
AU - Johnston, Wendy
AU - Snow, Hayden
AU - Haas, Rick L.
AU - Callegaro, Dario
AU - Smith, Myles J.
AU - Bouhadiba, Toufik
AU - Desai, Anant
AU - Voss, Rachel
AU - Sanfilippo, Roberta
AU - Jones, Robin L.
AU - Baldini, Elizabeth H.
AU - Wagner, Andrew J.
AU - Catton, Charles N.
AU - Stacchiotti, Silvia
AU - Thway, Khin
AU - Roland, Christina L.
AU - Raut, Chandrajit P.
AU - Gronchi, Alessandro
N1 - Publisher Copyright:
© 2022, Society of Surgical Oncology.
PY - 2022/11
Y1 - 2022/11
N2 - Background: Surgery is the mainstay of treatment for retroperitoneal sarcoma (RPS), but local recurrence is common. Biologic behavior and recurrence patterns differ significantly among histologic types of RPS, with implications for management. The Transatlantic Australasian RPS Working Group (TARPSWG) published a consensus approach to primary RPS, and to complement this, one for recurrent RPS in 2016. Since then, additional studies have been published, and collaborative discussion is ongoing to address the clinical challenges of local recurrence in RPS. Methods: An extensive literature search was performed, and the previous consensus statements for recurrent RPS were updated after review by TARPSWG members. The search included the most common RPS histologic types: liposarcoma, leiomyosarcoma, solitary fibrous tumor, undifferentiated pleomorphic sarcoma, and malignant peripheral nerve sheath tumor. Results: Recurrent RPS management was evaluated from diagnosis to follow-up evaluation. For appropriately selected patients, resection is safe. Nomograms currently are available to help predict outcome after resection. These and other new findings have been combined with expert recommendations to provide 36 statements, each of which is attributed a level of evidence and grade of recommendation. In this updated document, more emphasis is placed on histologic type and clarification of the intent for surgical treatment, either curative or palliative. Overall, the fundamental tenet of optimal care for patients with recurrent RPS remains individualized treatment after multidisciplinary discussion by an experienced team with expertise in RPS. Conclusions: Updated consensus recommendations are provided to help guide decision-making for treatment of locally recurrent RPS and better selection of patients who would potentially benefit from surgery.
AB - Background: Surgery is the mainstay of treatment for retroperitoneal sarcoma (RPS), but local recurrence is common. Biologic behavior and recurrence patterns differ significantly among histologic types of RPS, with implications for management. The Transatlantic Australasian RPS Working Group (TARPSWG) published a consensus approach to primary RPS, and to complement this, one for recurrent RPS in 2016. Since then, additional studies have been published, and collaborative discussion is ongoing to address the clinical challenges of local recurrence in RPS. Methods: An extensive literature search was performed, and the previous consensus statements for recurrent RPS were updated after review by TARPSWG members. The search included the most common RPS histologic types: liposarcoma, leiomyosarcoma, solitary fibrous tumor, undifferentiated pleomorphic sarcoma, and malignant peripheral nerve sheath tumor. Results: Recurrent RPS management was evaluated from diagnosis to follow-up evaluation. For appropriately selected patients, resection is safe. Nomograms currently are available to help predict outcome after resection. These and other new findings have been combined with expert recommendations to provide 36 statements, each of which is attributed a level of evidence and grade of recommendation. In this updated document, more emphasis is placed on histologic type and clarification of the intent for surgical treatment, either curative or palliative. Overall, the fundamental tenet of optimal care for patients with recurrent RPS remains individualized treatment after multidisciplinary discussion by an experienced team with expertise in RPS. Conclusions: Updated consensus recommendations are provided to help guide decision-making for treatment of locally recurrent RPS and better selection of patients who would potentially benefit from surgery.
KW - Adult
KW - Biological Products
KW - Humans
KW - Liposarcoma
KW - Neoplasm Recurrence, Local/surgery
KW - Retroperitoneal Neoplasms/pathology
KW - Retrospective Studies
KW - Sarcoma/pathology
KW - Soft Tissue Neoplasms
UR - http://www.scopus.com/inward/record.url?scp=85133808215&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000818612400001&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1245/s10434-022-11864-y
DO - 10.1245/s10434-022-11864-y
M3 - Article
C2 - 35767103
SN - 1068-9265
VL - 29
SP - 7335
EP - 7348
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 12
ER -